Swen Hoelder

Title: Swen Hoelder: Innovator in Kinase Inhibitors

Introduction

Swen Hoelder is a notable inventor based in Constance, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of kinase inhibitors. With a total of 8 patents to his name, Hoelder's work is recognized for its potential impact on cancer treatment.

Latest Patents

Among his latest patents, Hoelder has developed pyridazinone kinase inhibitors. These compounds are designed to treat various cancers and are characterized by a specific formula where X is defined along with other substituents. Another significant patent involves 4-benzimidazol-2-ylpyridazin-3-one derivatives. This patent details a process for preparing these compounds, which are also used as pharmaceuticals and are particularly effective as inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

Career Highlights

Throughout his career, Swen Hoelder has worked with prominent companies in the pharmaceutical industry, including Sanofi-Aventis Deutschland GmbH and Aventis Pharma S.A. His expertise in the field has led to the development of innovative solutions that address critical health challenges.

Collaborations

Hoelder has collaborated with several professionals in his field, including Karl Schoenafinger and David William Will. These collaborations have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Swen Hoelder's contributions to the field of kinase inhibitors highlight his role as an influential inventor in the pharmaceutical industry. His innovative work continues to pave the way for new treatments in cancer therapy.